GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Price-to-Tangible-Book

Antares Pharma (Antares Pharma) Price-to-Tangible-Book : 6.08 (As of Apr. 25, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Price-to-Tangible-Book?

As of today (2024-04-25), Antares Pharma's share price is $5.59. Antares Pharma's Tangible Book per Share of Mar. 2022 for the quarter that ended in Mar. 2022 was $0.92. Hence, Antares Pharma's Price to Tangible Book Ratio of today is 6.08.

The historical rank and industry rank for Antares Pharma's Price-to-Tangible-Book or its related term are showing as below:

ATRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62   Med: 7.78   Max: 1000
Current: 6.08

During the past 13 years, Antares Pharma's highest Price to Tangible Book Ratio was 1000.00. The lowest was 0.62. And the median was 7.78.

ATRS's Price-to-Tangible-Book is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 2.64 vs ATRS: 6.08

A closely related ratio is called PB Ratio. As of today, Antares Pharma's share price is $5.59. Antares Pharma's Book Value per Sharefor the quarter that ended in Mar. 2022 was $1.03. Hence, Antares Pharma's P/B Ratio of today is 5.43.


Antares Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Antares Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Price-to-Tangible-Book Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.05 11.72 14.69 6.04 3.87

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.85 5.92 4.63 3.87 4.46

Competitive Comparison of Antares Pharma's Price-to-Tangible-Book

For the Medical Instruments & Supplies subindustry, Antares Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Price-to-Tangible-Book falls into.



Antares Pharma Price-to-Tangible-Book Calculation

Antares Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2022 )
=5.59/0.92
=6.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Antares Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447